Ionis Pharmaceuticals, Inc. (IONS)
45.27
+1.97
(+4.55%)
USD |
NASDAQ |
Oct 09, 16:00
45.27
0.00 (0.00%)
After-Hours: 20:00
Ionis Pharmaceuticals Cash from Operations (Quarterly) : 565.53M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 565.53M |
| March 31, 2026 | -792.82M |
| December 31, 2025 | -137.71M |
| September 30, 2025 | -131.44M |
| June 30, 2025 | 151.34M |
| March 31, 2025 | -150.78M |
| December 31, 2024 | -116.14M |
| September 30, 2024 | -114.99M |
| June 30, 2024 | -119.88M |
| March 31, 2024 | -149.94M |
| December 31, 2023 | 32.86M |
| September 30, 2023 | -109.02M |
| June 30, 2023 | -97.36M |
| March 31, 2023 | -133.99M |
| December 31, 2022 | -200.20M |
| September 30, 2022 | -24.43M |
| June 30, 2022 | -18.10M |
| March 31, 2022 | -31.65M |
| December 31, 2021 | 203.69M |
| September 30, 2021 | -55.57M |
| June 30, 2021 | -62.65M |
| March 31, 2021 | -54.66M |
| December 31, 2020 | 97.98M |
| September 30, 2020 | -10.28M |
| June 30, 2020 | -44.22M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.592M |
| December 31, 2019 | 277.93M |
| September 30, 2019 | -12.81M |
| June 30, 2019 | -27.11M |
| March 31, 2019 | 107.70M |
| December 31, 2018 | 115.49M |
| September 30, 2018 | -26.00M |
| June 30, 2018 | 500.24M |
| March 31, 2018 | 13.16M |
| December 31, 2017 | 20.40M |
| September 30, 2017 | 28.72M |
| June 30, 2017 | 2.363M |
| March 31, 2017 | 122.66M |
| December 31, 2016 | -25.96M |
| September 30, 2016 | 23.41M |
| June 30, 2016 | -33.78M |
| March 31, 2016 | -75.77M |
| December 31, 2015 | -37.47M |
| September 30, 2015 | 36.22M |
| June 30, 2015 | 65.21M |
| March 31, 2015 | -42.83M |
| December 31, 2014 | 70.68M |
| September 30, 2014 | 1.944M |
| June 30, 2014 | -34.02M |
| March 31, 2014 | -32.33M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Biogen, Inc. | 448.90M |
| BridgeBio Pharma, Inc. | -71.10M |
| Vertex Pharmaceuticals, Inc. | 1.125B |
| Pfizer Inc. | 835.00M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 23.50M |
| Cash from Financing (Quarterly) | -412.29M |
| Free Cash Flow | -567.50M |
| Free Cash Flow Per Share (Quarterly) | 3.309 |
| Free Cash Flow to Equity (Quarterly) | 967.92M |
| Free Cash Flow to Firm (Quarterly) | 569.67M |
| Free Cash Flow Yield | -7.69% |